Merck acquires global rights to SciBrunch Therapeutics’ SPR2015, a preclinical oral KRAS G12D inhibitor, in a deal worth up ...

Merck said on Monday it would pay ​up to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for ...

The medicines Merck sells today grew at their usual pace. What investors spent the year repricing was everything that comes next.

Merck receives positive EU CHMP opinion for Keytruda plus Padcev as perioperative treatment for adults with resectable MIBC: Rahway, New Jersey Saturday, September 19, 2026, 11:00 ...

Conversations about cancer research are tough for anyone who has ever been diagnosed, treated, or lost someone to the disease ...

Diversifying income across genuinely uncorrelated cash-flow engines is more powerful than owning five versions of the same defensive stock.

Merck (NYSE:MRK) extends a monthly rally on Keytruda strength, encouraging melanoma trial results with Moderna, and a newly accepted regulatory submission expanding its RSV therapy indication.

Merck (MRK) stock: company licenses SciBrunch's cancer drug SPR2015 in a deal worth up to $2.13 billion, targeting KRAS G12D mutations.

Cancer vaccines show promise for melanoma, pancreatic, and colorectal cancer in Peoria and beyond, with new mRNA trials and ...

Merck (MRK) acquires worldwide rights to SPR2015 cancer drug from SciBrunch in deal valued at $2.13B, targeting common KRAS ...

By Akash Sriram and Mariam Sunny Sept 17 (Reuters) - As the International Space Station nears the end of its operational life ...

Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma. Tebentafusp-tebn (Kimmtrak) continued to confer an ...